217 related articles for article (PubMed ID: 28683239)
1. COMPARISON OF EFFICACY AND SAFETY OF GLARGINE AND DETEMIR INSULIN IN THE MANAGEMENT OF INPATIENT HYPERGLYCEMIA AND DIABETES.
Galindo RJ; Davis GM; Fayfman M; Reyes-Umpierrez D; Alfa D; Peng L; Tamler R; Pasquel FJ; Umpierrez GE
Endocr Pract; 2017 Sep; 23(9):1059-1066. PubMed ID: 28683239
[TBL] [Abstract][Full Text] [Related]
2. Detemir vs Glargine: Comparison of Inpatient Glycemic Control.
Capson J; Cade K; Avanesyan A
J Am Osteopath Assoc; 2019 Feb; 119(2):89-95. PubMed ID: 30688354
[TBL] [Abstract][Full Text] [Related]
3. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
[TBL] [Abstract][Full Text] [Related]
5. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
6. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
7. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
8. Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus.
Abalı S; Turan S; Atay Z; Güran T; Haliloğlu B; Bereket A
Pediatr Diabetes; 2015 Aug; 16(5):361-6. PubMed ID: 25039448
[TBL] [Abstract][Full Text] [Related]
9. Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice.
Rautiainen P; Tirkkonen H; Laatikainen T
Diabetes Technol Ther; 2018 May; 20(5):363-369. PubMed ID: 29741925
[TBL] [Abstract][Full Text] [Related]
10. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).
Shimoda S; Sato M; Sekigami T; Motoshima H; Yoshimura R; Fukuda K; Matsuo Y; Noda H; Okubo M; Ichimori S; Fujisawa K; Fukunaga M; Araki E;
J Diabetes Investig; 2016 Sep; 7(5):703-10. PubMed ID: 27181264
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Patients With Type 2 Diabetes in Long-term Care and Skilled Nursing Facilities: Linagliptin-LTC Trial.
Umpierrez GE; Cardona S; Chachkhiani D; Fayfman M; Saiyed S; Wang H; Vellanki P; Haw JS; Olson DE; Pasquel FJ; Johnson TM
J Am Med Dir Assoc; 2018 May; 19(5):399-404.e3. PubMed ID: 29289540
[TBL] [Abstract][Full Text] [Related]
12. [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Results of the nonintervention RESOLUTE Project in the Czech Republic].
Kvapil M
Vnitr Lek; 2013 Sep; 59(9):800-6. PubMed ID: 24073952
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study.
Umpierrez GE; Gianchandani R; Smiley D; Jacobs S; Wesorick DH; Newton C; Farrokhi F; Peng L; Reyes D; Lathkar-Pradhan S; Pasquel F
Diabetes Care; 2013 Nov; 36(11):3430-5. PubMed ID: 23877988
[TBL] [Abstract][Full Text] [Related]
14. Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors.
Zhang T; Ji L; Gao Y; Zhang P; Zhu D; Li X; Ji J; Zhao F; Zhang H; Guo X
Diabetes Technol Ther; 2017 Nov; 19(11):675-684. PubMed ID: 29090977
[TBL] [Abstract][Full Text] [Related]
15. Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes.
Derosa G; Franzetti I; Querci F; Romano D; D'Angelo A; Maffioli P
Diabetes Obes Metab; 2015 Jun; 17(6):554-559. PubMed ID: 25694300
[TBL] [Abstract][Full Text] [Related]
16. Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes.
Smiley D; Umpierrez GE; Hermayer K; Newton C; Jacobs S; Olson DE; Khan A; Rizzo M; Peng L; Reyes D; Cardona S; Fonseca V
J Diabetes Complications; 2013; 27(6):637-41. PubMed ID: 23911535
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial.
Pasquel FJ; Lansang MC; Khowaja A; Urrutia MA; Cardona S; Albury B; Galindo RJ; Fayfman M; Davis G; Migdal A; Vellanki P; Peng L; Umpierrez GE
Diabetes Care; 2020 Jun; 43(6):1242-1248. PubMed ID: 32273271
[TBL] [Abstract][Full Text] [Related]
18. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
[TBL] [Abstract][Full Text] [Related]
19. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
King AB
Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
[TBL] [Abstract][Full Text] [Related]
20. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
Meneghini L; Kesavadev J; Demissie M; Nazeri A; Hollander P
Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
